(Q37772508)

22 August 2017

1 reference

title

Management of HIV and hepatitis virus coinfection (English)

1 reference

22 August 2017

MariaCássia Mendes-Corrêa

series ordinal

1

1 reference

PubMed ID

20629586

22 August 2017

Marina Núñez

series ordinal

2

1 reference

PubMed ID

20629586

22 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

1 reference

22 August 2017

11

1 reference

22 August 2017

2497-2516

1 reference

22 August 2017

15

1 reference

Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Hepatitis B and long-term HIV outcomes in coinfected HAART recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Telbivudine has activity against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Renal safety of tenofovir in HIV treatment-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Management of hepatitis B: summary of a clinical research workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Indications for therapy in hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Renal function with use of a tenofovir-containing initial antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Benefits and risks of combination therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

HIV and hepatitis C coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Management of chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Ribavirin antagonizes the effect of azidothymidine on HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Treatment of acute hepatitis C in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Acute hepatitis C and HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Human immunodeficiency virus and liver transplantation: our point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Outcomes after orthotopic liver transplantation in 15 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.500615

10.1517/14656566.2010.500615

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20629586